Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

A new daily pill for obesity, orforglipron, has shown promising results in a major clinical trial, helping patients lose ...

The National Institute for Health and Care Excellence (Nice) said people finishing treatment through the NHS must receive ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

New NHS guidance warns that people coming off weight-loss medications such as Wegovy ( semaglutide) and Mounjaro ( ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those trying to lose weight. But a rise in so-called "Ozempic babies" has led ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

As of July 1, CVS Caremark — one of the biggest pharmacy benefit managers in the U.S. — dropped Zepbound (tirzepatide) from its preferred drug list, replacing it with Wegovy (semaglutide).